AUROBAC THERAPEUTICS Unveils R&D Strategy, Pipeline, and Partnership with Boehringer Ingelheim

June 3, 2024, Lyon, France - AUROBAC THERAPEUTICS, a biopharmaceutical company established by Boehringer Ingelheim, bioMérieux, and Evotec, has introduced its comprehensive approach to addressing critical medical needs in acute hospital settings. With a focus on the escalating issue of antimicrobial resistance (AMR), AUROBAC THERAPEUTICS aims to develop innovative treatments for serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP), and sepsis.

Central to AUROBAC’s strategy is the implementation of pioneering diagnostic techniques, developed in collaboration with bioMérieux. These methods will facilitate patient stratification and enhance treatment outcomes. The company has also announced a new partnership and licensing agreement for a Boehringer Ingelheim compound, which will be advanced as ATX101 for the treatment of septic shock. ATX101 is a promising candidate believed to address the loss of vascular integrity in septic shock, and AUROBAC THERAPEUTICS plans to initiate clinical trials in 2025.

Alongside ATX101, AUROBAC is progressing its discovery and early preclinical pipeline, featuring ATX401 (formerly CF-370). This compound is noteworthy as the first engineered lysin with significant activity against various Gram-negative bacteria in vitro. These bacteria, known for their resilient outer membrane, often resist conventional antibiotics. ATX401 has the capability to breach this barrier and destroy bacterial cells, leading to their elimination.

Additionally, AUROBAC’s distinctive drug discovery platform aims to identify new precision antimicrobials. This initiative is highlighted by a partnership with GENERARE Bioscience, utilizing their DNA-guided synthetic biology platform to discover novel antimicrobial agents.

Martin Everett, Ph.D., AUROBAC’s Chief Scientific Officer, emphasized the urgent need for new therapies to combat Gram-negative resistant infections in hospitals. He highlighted the company's diagnostic-driven strategy and innovative pipeline as essential to developing next-generation, precision drugs to enhance patient outcomes.

Today's announcements reflect AUROBAC’s ongoing commitment to fostering collaborations and partnerships, as it pursues its mission to develop and market groundbreaking products targeting bacterial infections and AMR in acute hospital settings.

About AUROBAC THERAPEUTICS:
AUROBAC THERAPEUTICS, established in 2022 by Boehringer Ingelheim, Evotec, and bioMérieux, aims to become a leader in combating bacterial infections and antimicrobial resistance in acute hospital environments.

About Sepsis:
Sepsis, a severe condition characterized by extreme organ dysfunction due to an overwhelming response to infection, affects 47 to 50 million people annually and is associated with roughly 20% of global deaths. In the USA, sepsis care costs exceed $24 billion each year.

About AMR:
Antimicrobial Resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi, and parasites develop resistance to antimicrobial medications. This phenomenon, driven by the misuse and overuse of antimicrobials, poses a significant global health threat. AMR currently causes over 1.27 million deaths annually and could lead to 10 million deaths per year by 2050, equating to the current annual global cancer death toll. The economic impact is substantial, with the World Bank estimating an additional US$ 1 trillion in healthcare costs by 2050 if not controlled.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!